Interleukin-18: A potent pro-inflammatory cytokine in atherosclerosis

Cardiovascular Research

Volumn 96, Issue 2, 2012, Pages 172-175

  Badimon, Lina ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; INTERLEUKIN 12; INTERLEUKIN 18; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ATHEROSCLEROSIS; AUTOPHOSPHORYLATION; CD4+ T LYMPHOCYTE; CONGESTIVE HEART FAILURE; GENETIC TRANSCRIPTION; HUMAN; KUPFFER CELL; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; T LYMPHOCYTE; TH1 CELL;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; INTERLEUKIN-18; MALE; MUSCLE, SMOOTH, VASCULAR; TH1 CELLS;

EID: 84867712592     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs226     Document Type: Review

References (31)

1. Seta Y, Kanda T, Tanaka T, Arai M, Sekiguchi K, Yokoyama T et al. Interleukin 18 in acute myocardial infarction. Heart 2000;84:668.
2. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001;104:1598-1603.
3. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001;89:E41-E45.
4. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (il)-18 and functional il-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002;195:245-257.
5. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein e(2/2) mice through release of interferon-gamma. Circ Res 2002;90: E34-E38.
6. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda K, Akira S et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein e-knockout mice. Cardiovasc Res 2003;59:234-240.
7. Hansson GK, Holm J, Jonasson L. Detection of activated t lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989;135:169-175.
8. Nakamura K, Okamura H, Wada M, Nagata K, Tamura T. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect Immun 1989;57:590-595.
9. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T et al. Cloning of a new cytokine that induces ifn-gamma production by t cells. Nature 1995;378:88-91.
10. Seta Y, Kanda T, Tanaka T, Arai M, Sekiguchi K, Yokoyama T et al. Interleukin-18 in patients with congestive heart failure: induction of atrial natriuretic peptide gene expression. Res Commun Mol Pathol Pharmacol 2000;108:87-95.
11. Torigoe K, Ushio S, Okura T, Kobayashi S, Taniai M, Kunikata T et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem 1997;272: 25737-25742.
12. Born TL, Thomassen E, Bird TA, Sims JE. Cloning of a novel receptor subunit, acpl, required for interleukin-18 signaling. J Biol Chem 1998;273:29445-29450.
13. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S et al. Myd88 is an adaptor protein in the htoll/il-1 receptor family signaling pathways. Mol Cell 1998;2: 253-258.
14. Dinarello CA, Fantuzzi G. Interleukin-18 and host defense against infection. J Infect Dis 2003;187(Suppl. 2):S370-S384.
15. KojimaH,Takeuchi M,OhtaT, NishidaY, Arai N, IkedaMet al. Interleukin-18 activates the irak-traf6 pathway in mouse el-4 cells. Biochem Biophys Res Commun 1998;244:183-186.
16. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a novel modulator of the th1 cytokine response. Immunity 1999;10:127-136.
17. Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M et al. Structural requirements of six naturally occurring isoforms of the il-18 binding protein to inhibit il-18. Proc Natl Acad Sci USA 2000;97:1190-1195.
18. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003;73:213-224.
19. Mason DR, Beck PL, Muruve DA. Nucleotide-binding oligomerization domain-like receptors and inflammasomes in the pathogenesis of non-microbial inflammation and diseases. J Innate Immun 2012;4:16-30.
20. De Nardo D, Latz E. Nlrp3 inflammasomes link inflammation and metabolic disease. Trends Immunol 2011;32:373-379.
21. Wassel CL, Lange LA, Keating BJ, Taylor KC, Johnson AD, Palmer C et al. Association of genomic loci from a cardiovascular gene snp array with fibrinogen levels in European Americans and African-Americans from six cohort studies: the candidate gene association resource (care). Blood 2011;117:268-275.
22. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821-832.
23. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
24. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P et al. Interleukin-18 and the risk of coronary heart disease in European men: the prospective epidemiological study of myocardial infarction (prime). Circulation 2003;108: 2453-2459.
25. Chapman CM, McQuillan BM, Beilby JP, Thompson PL, Hung J. Interleukin-18 levels are not associated with subclinical carotid atherosclerosis in a community population. The perth carotid ultrasound disease assessment study (cudas). Atherosclerosis 2006; 189:414-419.
26. Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schonbeck U, Khera A et al. Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the dallas heart study. Arterioscler Thromb Vasc Biol 2007;27:2043-2049.
27. Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011;105(Suppl. 1):S34-S42.
28. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-2138.
29. Badimon L, Vilahur G. Ldl-cholesterol versus hdl-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. Ann N Y Acad Sci 2012; 1254:18-32.
30. Libby P, Crea F. Clinical implications of inflammation for cardiovascular primary prevention. Eur Heart J 2010;31:777-783.
31. Klingenberg R, Hansson GK. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009;30:2838-2844.